NCT02291588View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

June 30, 2010

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

AMG 811

A single dose of AMG 811 or placebo will be adminstered.

DRUG

Placebo

contains no active drug

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY